Abstract
Chugai is developing ED-71, an orally available vitamin D3 derivative, for the potential treatment of osteoporosis. By December 2003, the compound had entered phase III trial for the prevention of fracture.
MeSH terms
-
Animals
-
Calcitriol / analogs & derivatives*
-
Calcitriol / chemistry*
-
Calcitriol / pharmacology
-
Calcitriol / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Humans
-
Osteoporosis / drug therapy
-
Osteoporosis / prevention & control
-
Receptors, Calcitriol / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Vitamin D / analogs & derivatives
Substances
-
Receptors, Calcitriol
-
Vitamin D
-
Calcitriol
-
eldecalcitol